AT EVERY STEP OF THE RESEARCH PROCESS FROM THE LAB TO THE CLINIC, WE ARE PURSUING INNOVATIVE WAYS TO PREVENT AND CONTROL CANCER.
Ludwig Harvard researchers have discovered a metabolic weakness in triple-negative breast cancer (TNBC) cells that may be exploited to quell their resistance to chemotherapy.
Ludwig San Diego researchers discover that circular DNA, once thought to be rare in tumor cells, is actually very common and seems to play a fundamental role in tumor evolution.
Chi Van Dang will join Ludwig as Scientific Director on July 1, 2017. A hematological oncologist and renowned researcher, Dang joins Ludwig from the University of Pennsylvania’s Abramson Cancer Center, which he has directed since 2011.